News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Article excerpt: "Cryoablation was the only thermal ablative technique that met the minimum requirements and will therefore be selected for the Phase 3 trial.". Go Israel! Steady she goes..
Steady climb. Quiet beast...
More good news,
"https://ih.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/stock-news/95043638/icecures-prosense-cryoablation-safe-and-effective"
Boing X 2
Oh boy, multiple probes approved for large tumors in Japan.
https://ih.advfn.com/stock-market/NASDAQ/icecure-medical-ICCM/stock-news/94979474/icecures-next-generation-multiprobe-cryoablation-t
Boing X 2
I read the 35 medical submissions recommending approval of our system and they are very positive. Having worked in the medical field during my working years I am very positive on our chances to get approval. There needs to be a less invasive procedure available.
As I have said before, I would have much rather had this procedure on my lung tumor if it would have worked for me vs. radiation and its side effects. Too close to my pulmonary artery though. IMHO, here is a good case for approval with the improvements in early discovery of tumors now.
Boing X 2
Should hold around here I can't see it getting lower than .55 cents!
LFG got 45% of my portfolio in here now!
I can't see the company hitting their ATM at .60!
$ICCM
Added 260k shares the last week. You guys ready for that trend reversal.
November 7th FDA Panel Meeting
FDA approval January
$ICCM
IceCure initial addressable market for early stage is 70,000 breast cancer patients per year in the US.
Tumor Ablation Market Expected to Reach $2.4B by 2028 from 1.1 Billion in 2021
US Cryoablation Market 2024
Breast Tumors =Approximately 310,000 new invasive breast cancer patients.
U.S. clinical market analysis of invasive breast cancer
Low risk, early stage, T1 invasive breast cancer
Initial addressable market of 70,000 breast cancer
patients per year in the U.S.
• 310,720 new cases of invasive breast cancer will be
diagnosed in 2024 in the U.S.¹
• Luminal-A is the most common breast cancer
subtype and represents 50-60% of all breast
cancers.
• Tumor size distribution suggests that T1(2cm or
smaller) is 67% of all breast cancers tumors.
IceCure additional markets:
• 81,610 new kidney cases
• 41,630 new liver cancer cases
• 234,580 new lung cancer cases
Cryogenics is used by tens of millions of people for recovery whether its ice bath freezing chambers or cold plunges freezing and killing cancer tumors will trend up as cancer patients realize more natural organic way that has much better results than any medications on the market and minus the major side effects IceCure has 97% Complete Response rate for cancer patients that's compared to Mercks Keytruda for 38% response rate.
IceCure Biz Presentation
https://d1io3yog0oux5.cloudfront.net/_645bffe72972ea00b5b9677cd4a4444b/icecuremedical/db/2291/21959/pdf/IceCure+Medical+%28ICCM%29+Company+Presentation+-+29-Aug-2024+FINAL.pdf
$ICCM
Peer Reviewed Paper Published today in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Cryogenics treatment will be a game changer in Breast Cancer and other oncology indications Freezing and Killing cancerous Tumors! ( No surgeries or medications with ill side effects and low efficacy)
Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 2024
96.3% recurrence free rate for women treated with ProSense® cryoablation and endocrine therapy; 100% of patients and treating physicians were satisfied with the cosmetic outcome.
Lead study author, Dr. Richard E. Fine, is an ICE3 investigator and winner of the 2024 American Society of Breast Surgeons' Scientific Impact Award for his presentation of the ICE3 trial data.
ProSense® offers women the choice of a quick minimally invasive in-office procedure under local anesthesia with minimal pain, minimal scarring and rapid recovery as compared to lumpectomy which involves full anesthesia and hours of surgery and recovery, followed by 1-2 weeks of limited movement.
Key highlights and findings from the Peer Reviewed article include:
194 patients meeting eligibility received successful cryoablation treatment per protocol and were included in the final results for analysis.
The mean age was 74.9 years (55–94) with a mean tumor size of 7.4 mm transverse (2.8–14.0 mm) and 8.1 mm sagittal (2.5–14.9 mm).
With a mean follow-up period of 54.16 months for the total population of the ICE3 trial, the IBTR rate at 5 years was 4.3% and breast cancer survival was 96.7%.
Of the 124 patients who received cryoablation and endocrine therapy, the IBTR was 3.7%, resulting in a recurrence-free rate of 96.3%.
No serious device-related adverse events were reported.
Quality-of-life score demonstrated statistically significant improvement (p < 0.001) in distress at 6 months as compared with baseline.
100% of patients and treating physicians were satisfied with the cosmetic outcome.
ICE3 is a non-randomized trial that was conducted at 19 sites in the U.S.
IceCure 30 Million market cap
PLSE 1.1 Billion market cap was a 30 million dollar company a few years ago.
Billionaires are majority shareholders in both companies
IceCure Medical's ProSense Cryoablation System the next paradigm in Oncology works better than surgery or any Pill or antibody treatment
52 week high of 1.57 will be taken out soon. A safe in office Cryo Freezing Platform that is done in an hour with no anesthesia that kills nearly 100% of Tumors for a wide array of cancer indications including Breast Lung, Kidney and Liver Tumors over a half of dozen independent studies including one from Oxford that go out 5 years and counting from prestigious world renown establishments all over the world showcasing identical data points works better than any cancer drug on the market and importantly safer than any pill or IV treatment in the world. Patents Valid through 2041 Could see 1000-2000% upside from these levels. I have seen it with PLSE $1.18- $45.00 low to high this technology IceCure technology is the real deal and has the Data to prove it! Plus the Cryoblation is reasonably priced. compared to some cancer medicines that cost hundreds of thousands of dollars some cost Millions. Don't wait for the stock to move hundreds of percent up from here!. timing is everything. FDA Panel meeting and Approval near term.
$ICCM
97% Complete response by freezing & Tumor kiling rate for Breast Cancer safer after 5 years no Pill or IV based medication in efficacy comes close to IceCure Cryoblation Platform.
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues.
Published by Oxford University Press on behalf of the British Institute of Radiology.
https://finance.yahoo.com/news/study-published-british-journal-radiology-120000504.html
IceCure Medical's ProSense Cryoablation System
FDA Approval coming.
Billionaire who founded Tencent Victor Li owns half the shares.
Freezing Cancer
in its Tracks.
Enabling non-surgical treatment of
Cancerous tumors!
Treats Breast, Kidne, Lung and other cancer indications!
No debt no warrants.
Partnered with Medtronic already in Asia
IceCure Medical, Shanghai Medtronic & Turing Medical Sign Distribution Agreement in Mainland China.
People are realizing minimally invasive platforms are the approach to treating cancer and other diseases.
You can get the treatment done for a few thousand dollars in less than hour with a local anesthetic no anesthesia. and be home within a couple of hours.
Independent 5 year data for breast cancer showing 97% non recurrence rate SAFE am alternative too million dollar plus gene editing treatments and or pills or IV that are expensive and have many major side effects. There are now over half dozen studies done in many countries proving the platform and Data!
PLSE went from $1.00-20.00 2-3 year period they have a billion market cap and no revenue.
ICCM is going has tremendous upside also Japanese approval process starts in January with the largest device company in Japan company Terumo. FDA panel meeting in early November with ICCM and FDA Approval can come late 2024 or January next year!
https://www.prnewswire.com/il/news-releases/icecure-medical-reports-positive-topline-results-from-ice3-cryoablation-breast-cancer-study-achievement-of-96-39-recurrence-free-rate-brings-company-one-step-closer-to-providing-women-a-non-surgical-alternative-to-lumpectomy-302092712.html
https://www.icecure-medical.com/
https://d1io3yog0oux5.cloudfront.net/_bc04737bc474935b6b12dfea965ac04e/icecuremedical/db/2291/21959/pdf/IceCure+Medical+%28ICCM%29+Company+Presentation+-+29-Aug-2024+FINAL.pdf
(Watch this Testimonial Video)
$ICCM is in a good loading zone right now.
|
Followers
|
24
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
324
|
|
Created
|
01/20/20
|
Type
|
Free
|
| Moderators | |||
AI
